Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.
- Resource Type
- Article
- Authors
- Prabhu, Vimalanand S.; Cornely, Oliver A.; Golan, Yoav; Dubberke, Erik R.; Heimann, Sebastian M.; Hanson, Mary E.; Liao, Jane; Pedley, Alison; Dorr, Mary Beth; Marcella, Stephen
- Source
- Clinical Infectious Diseases. Oct2017, Vol. 65 Issue 7, p1218-1221. 4p.
- Subject
- *THERAPEUTIC use of monoclonal antibodies
*ANTIBIOTICS
*CLOSTRIDIOIDES difficile
*CLOSTRIDIUM diseases
*CONFIDENCE intervals
*RESEARCH funding
*STATISTICS
*DATA analysis
*SECONDARY analysis
*PATIENT readmissions
*DESCRIPTIVE statistics
*LEUKOCYTE count
- Language
- ISSN
- 1058-4838
We estimated 30-day all-cause and Clostridium difficile infection (CDI)-associated hospital readmissions in participants at high risk of recurrent CDI enrolled in MODIFY I/II. Bezlotoxumabtreated inpatients experienced fewer CDI-associated readmissions compared with placebo-treated inpatients, notably in participants aged =65 years and with severe CDI. [ABSTRACT FROM AUTHOR]